|
BRPI0906473A8
(pt)
|
2008-01-04 |
2016-02-10 |
Intellikine Inc |
Certas entidades químicas, composições e métodos
|
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
|
WO2010036380A1
(en)
|
2008-09-26 |
2010-04-01 |
Intellikine, Inc. |
Heterocyclic kinase inhibitors
|
|
JP5789252B2
(ja)
|
2009-05-07 |
2015-10-07 |
インテリカイン， エルエルシー |
複素環式化合物およびその使用
|
|
RU2573569C2
(ru)
*
|
2009-12-22 |
2016-01-20 |
Вертекс Фармасьютикалз Инкорпорейтед |
Ингибиторы фосфатидилинозитол-3-киназы на основе изоиндолинона
|
|
JP5951600B2
(ja)
|
2010-05-21 |
2016-07-13 |
インフィニティー ファーマシューティカルズ， インコーポレイテッド |
キナーゼ調節のための、化合物、組成物および方法
|
|
WO2012064973A2
(en)
|
2010-11-10 |
2012-05-18 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2012088266A2
(en)
|
2010-12-22 |
2012-06-28 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
|
|
EP3238722B1
(en)
|
2011-01-10 |
2019-03-13 |
Infinity Pharmaceuticals, Inc. |
Solid forms of isoquinolinones
|
|
EP2734520B1
(en)
|
2011-07-19 |
2016-09-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
US9056877B2
(en)
|
2011-07-19 |
2015-06-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
PE20141371A1
(es)
|
2011-08-29 |
2014-10-13 |
Infinity Pharmaceuticals Inc |
Compuestos heterociclicos y usos de los mismos
|
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
ES2645984T3
(es)
*
|
2012-04-25 |
2017-12-11 |
Raqualia Pharma Inc |
Derivados de pirrolopiridinona como bloqueadores de TTX-S
|
|
CA2876689C
(en)
|
2012-06-13 |
2022-04-26 |
Incyte Corporation |
Substituted tricyclic compounds as fgfr inhibitors
|
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
UA110688C2
(uk)
*
|
2012-09-21 |
2016-01-25 |
Пфайзер Інк. |
Біциклічні піридинони
|
|
RU2702908C2
(ru)
|
2012-11-01 |
2019-10-14 |
Инфинити Фармасьютикалз, Инк. |
Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
|
US9481667B2
(en)
|
2013-03-15 |
2016-11-01 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
|
PH12015502383B1
(en)
|
2013-04-19 |
2023-02-03 |
Incyte Holdings Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
RU2675814C2
(ru)
|
2013-09-25 |
2018-12-25 |
Вертекс Фармасьютикалз Инкорпорейтед |
6,7-ДИГИДРО-5Н-ПИРРОЛО[3,4-b]ПИРИДИН-5-ОН, ПОЛЕЗНЫЙ В КАЧЕСТВЕ СЕЛЕКТИВНОГО ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ-ГАММА
|
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
EP3964507A1
(en)
|
2013-10-04 |
2022-03-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Ｋｒａｓ ｇ１２ｃ之抑制劑
|
|
CN106456628A
(zh)
|
2014-03-19 |
2017-02-22 |
无限药品股份有限公司 |
用于治疗PI3K‑γ介导的障碍的杂环化合物
|
|
WO2015160307A1
(en)
*
|
2014-04-16 |
2015-10-22 |
Nanyang Technological University |
Allenamide as an orthogonal handle for selective modification of cysteine in peptides and proteins
|
|
WO2015160975A2
(en)
|
2014-04-16 |
2015-10-22 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
ES2811088T3
(es)
|
2014-04-23 |
2021-03-10 |
Takeda Pharmaceuticals Co |
Derivados de isoindolin-1-ona como actividad del modulador alostérico positivo del receptor M1 muscarínico colinérgico para el tratamiento de la enfermedad de Alzheimer
|
|
CA2952044C
(en)
*
|
2014-06-13 |
2019-01-29 |
Gilead Sciences, Inc. |
Phosphatidylinositol 3-kinase inhibitors
|
|
CA2952025A1
(en)
|
2014-06-13 |
2015-12-17 |
Gilead Sciences, Inc. |
Phosphatidylinositol 3-kinase inhibitors
|
|
MX2016016538A
(es)
|
2014-06-13 |
2017-05-01 |
Gilead Sciences Inc |
Derivados de quinazolinona como inhibidores de fosfatidilinositol 3-cinasa.
|
|
US11021467B2
(en)
|
2014-06-13 |
2021-06-01 |
Gilead Sciences, Inc. |
Phosphatidylinositol 3-kinase inhibitors
|
|
MX2016016516A
(es)
|
2014-06-13 |
2017-05-01 |
Gilead Sciences Inc |
Inhibidores de fosfatidilinositol 3-cinasa.
|
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
CA2976790C
(en)
|
2015-02-20 |
2024-02-27 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
AU2016245864C1
(en)
|
2015-04-10 |
2021-09-09 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
ES2856880T3
(es)
|
2015-04-15 |
2021-09-28 |
Araxes Pharma Llc |
Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
WO2017045955A1
(en)
*
|
2015-09-14 |
2017-03-23 |
Basf Se |
Heterobicyclic compounds
|
|
CN114230571B
(zh)
|
2015-09-14 |
2025-07-08 |
无限药品股份有限公司 |
异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
|
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10730867B2
(en)
|
2015-09-28 |
2020-08-04 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
US10975071B2
(en)
|
2015-09-28 |
2021-04-13 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356347A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356359B1
(en)
|
2015-09-28 |
2021-10-20 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10514986B2
(en)
|
2015-09-30 |
2019-12-24 |
Commvault Systems, Inc. |
Dynamic triggering of block-level backups based on block change thresholds and corresponding file identities in a data storage management system
|
|
WO2017068412A1
(en)
|
2015-10-21 |
2017-04-27 |
Otsuka Pharmaceutical Co., Ltd. |
Benzolactam compounds as protein kinase inhibitors
|
|
JP2018531266A
(ja)
*
|
2015-10-22 |
2018-10-25 |
セルビタ エス．エー． |
ピリドン誘導体およびキナーゼ阻害剤としてのその使用
|
|
KR102932353B1
(ko)
|
2015-11-16 |
2026-02-27 |
아락세스 파마 엘엘씨 |
치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
|
|
WO2017107087A1
(en)
*
|
2015-12-23 |
2017-06-29 |
Merck Sharp & Dohme Corp. |
6, 7-dihydro-5h-pyrrolo [3, 4-b] pyridin-5-oneallosteric modulators of the m4 muscarinic acetylcholine receptor
|
|
EP3394061B1
(en)
|
2015-12-23 |
2020-03-11 |
Merck Sharp & Dohme Corp. |
6,7-dihydro-5h-pyrrolo[3,4-b]pyridin-5-one allosteric modulators of the m4 muscarinic acetylcholine receptor
|
|
WO2017107089A1
(en)
*
|
2015-12-23 |
2017-06-29 |
Merck Sharp & Dohme Corp. |
3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
|
|
BR112018068075A2
(pt)
*
|
2016-03-10 |
2019-01-08 |
Astrazeneca Ab |
inibidores de fosfatidilinositol 3-quinase gama
|
|
RS60825B1
(sr)
|
2016-03-17 |
2020-10-30 |
Hoffmann La Roche |
Aktivnost derivata 5-etiol-4-metil-pirazol-3-karboksamida kao agonista taar-a
|
|
WO2017161116A1
(en)
|
2016-03-17 |
2017-09-21 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
|
|
GB201604970D0
(en)
|
2016-03-23 |
2016-05-04 |
Syngenta Participations Ag |
Improvements in or relating to organic compounds
|
|
US10919914B2
(en)
|
2016-06-08 |
2021-02-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
EP3474856B1
(en)
|
2016-06-24 |
2022-09-14 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
JP2019529484A
(ja)
|
2016-09-29 |
2019-10-17 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤
|
|
US10377743B2
(en)
*
|
2016-10-07 |
2019-08-13 |
Araxes Pharma Llc |
Inhibitors of RAS and methods of use thereof
|
|
WO2018112842A1
(en)
|
2016-12-22 |
2018-06-28 |
Merck Sharp & Dohme Corp. |
6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
|
|
WO2018112843A1
(en)
|
2016-12-22 |
2018-06-28 |
Merck Sharp & Dohme Corp. |
Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
|
|
EP3573971A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
|
JP7327802B2
(ja)
|
2017-01-26 |
2023-08-16 |
アラクセス ファーマ エルエルシー |
縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
|
|
EP3573954A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
GB201706327D0
(en)
|
2017-04-20 |
2017-06-07 |
Otsuka Pharma Co Ltd |
A pharmaceutical compound
|
|
CN110869358A
(zh)
|
2017-05-25 |
2020-03-06 |
亚瑞克西斯制药公司 |
Kras的共价抑制剂
|
|
TW201906832A
(zh)
|
2017-05-25 |
2019-02-16 |
美商亞瑞克西斯製藥公司 |
用於癌症治療之化合物及其使用方法
|
|
WO2018218069A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant kras, hras or nras
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
US10945771B2
(en)
|
2017-06-09 |
2021-03-16 |
Merck Sharp & Dohme Corp. |
Azabicyclo[4.1.0]heptane allosteric modulators of the M4 muscarinic acetylcholine receptor
|
|
JP6647738B2
(ja)
|
2017-06-12 |
2020-02-14 |
矢崎総業株式会社 |
電池パック
|
|
WO2019000238A1
(en)
*
|
2017-06-27 |
2019-01-03 |
Merck Sharp & Dohme Corp. |
5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
|
|
WO2019000236A1
(en)
|
2017-06-27 |
2019-01-03 |
Merck Sharp & Dohme Corp. |
ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
|
|
WO2019000237A1
(en)
*
|
2017-06-27 |
2019-01-03 |
Merck Sharp & Dohme Corp. |
ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
|
|
KR20210028144A
(ko)
*
|
2018-04-06 |
2021-03-11 |
블랙 벨트 티엑스 리미티드 |
Atf6 저해제 및 그의 용도
|
|
KR102956194B1
(ko)
|
2018-05-04 |
2026-04-23 |
인사이트 코포레이션 |
Fgfr 억제제의 염
|
|
RS66310B1
(sr)
|
2018-05-04 |
2025-01-31 |
Incyte Corp |
Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
|
|
BR112021001709A2
(pt)
|
2018-08-01 |
2021-05-04 |
Araxes Pharma Llc |
compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
|
|
WO2020102216A1
(en)
|
2018-11-13 |
2020-05-22 |
Incyte Corporation |
Substituted heterocyclic derivatives as pi3k inhibitors
|
|
WO2020102198A1
(en)
|
2018-11-13 |
2020-05-22 |
Incyte Corporation |
Heterocyclic derivatives as pi3k inhibitors
|
|
US11161838B2
(en)
|
2018-11-13 |
2021-11-02 |
Incyte Corporation |
Heterocyclic derivatives as PI3K inhibitors
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
WO2020210379A1
(en)
|
2019-04-10 |
2020-10-15 |
Hangzhou Zhengxiang Pharmaceuticals Co., Ltd. |
Phosphatidylinositol 3-kinase inhibitors
|
|
AU2020288610A1
(en)
|
2019-06-04 |
2022-01-27 |
Arcus Biosciences, Inc. |
2,3,5-trisubstituted pyrazolo[1,5-a]pyrimidine compounds
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
US12122767B2
(en)
|
2019-10-01 |
2024-10-22 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
GEP20247679B
(en)
|
2019-10-14 |
2024-10-10 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2021113479A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
MX2022006691A
(es)
|
2019-12-04 |
2022-09-19 |
Incyte Corp |
Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
AU2021263914B2
(en)
|
2020-04-29 |
2026-07-23 |
D.E. Shaw Research, Llc |
PI3K-α inhibitors and methods of use thereof
|
|
EP4249481A4
(en)
*
|
2020-11-20 |
2024-10-30 |
Hefei Institutes of Physical Science, Chinese Academy of Sciences |
DIHYDROISOQUINOLINONE AND ISOINDOLINONE DERIVATIVES AND USES THEREOF
|
|
EP4308115A4
(en)
*
|
2021-03-17 |
2025-01-22 |
Merck Sharp & Dohme LLC |
HETEROAROYL AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
|
|
EP4323405A1
(en)
|
2021-04-12 |
2024-02-21 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
CA3220274A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
TW202313610A
(zh)
|
2021-06-09 |
2023-04-01 |
美商英塞特公司 |
作為ｆｇｆｒ抑制劑之三環雜環
|
|
US20260131009A1
(en)
*
|
2021-11-03 |
2026-05-14 |
Relay Therapeutics, Inc. |
Bifunctional pi3k-alpha inhibitors and uses thereof
|
|
WO2023098880A1
(zh)
*
|
2021-12-02 |
2023-06-08 |
上海翰森生物医药科技有限公司 |
稠环类衍生物调节剂、其制备方法和应用
|
|
KR102670554B1
(ko)
*
|
2022-01-04 |
2024-05-30 |
주식회사 이노보테라퓨틱스 |
캐스파제 저해제로서의 신규한 이소인돌리논 유도체 화합물
|
|
US20250171444A1
(en)
*
|
2022-03-04 |
2025-05-29 |
Synnovation Therapeutics, Inc. |
PI3Ka INHIBITORS
|
|
EP4585596A4
(en)
*
|
2022-09-09 |
2025-12-10 |
Shanghai Yingli Pharm Co Ltd |
Nitrogen-containing heterocyclic compound, pharmaceutical composition thereof and uses thereof
|
|
WO2024153238A1
(zh)
*
|
2023-01-20 |
2024-07-25 |
南京再明医药有限公司 |
四环化合物及其应用
|
|
WO2024251212A1
(en)
*
|
2023-06-06 |
2024-12-12 |
Revir Therapeutics, Inc. |
Isoindolinone and dihydropyrrolopridinone compounds and uses thereof
|
|
WO2025179441A1
(zh)
*
|
2024-02-27 |
2025-09-04 |
上海璎黎药业有限公司 |
一种三并环结构化合物、其药物组合物及应用
|